Shenzhen Lifotronic Technology (688389) Stock Overview

Shenzhen Lifotronic Technology Co., Ltd. develops, manufactures, and markets medical devices for diagnostic and therapeutic purposes in China. The company offers IVD products, such as HPLC systems, including hemoglobin and HbA1c analyzers, ECLIA systems comprising automated ECL immunoassay analyzers; hematology analyzers; POCT, such as immunofluorescence analyzers; molecular diagnostics, including automated nucleic acid purification system and real-time PCR systems; and rapid tests for COVID-19, malaria, dengue, and influenza A and B. It also provides therapeutic products comprising respiratory and ICU products, such as video laryngoscope, warmer unit with disposable blanket, high-flow humidification systems, high frequency chestwall oscillation, and intermittent pneumatic compression pumps; wound care products, including negative pressure wound therapy, ultrasound-assisted wound debridement, and wound healing light therapy; and ESWT pain management products comprising electromagnetic shockwave and extracorporeal shock wave therapy. In addition, the company's medical and aesthetic laser products comprises of intensive pulse light, fractional CO2 laser systems, Q-switched Nd:YAG laser systems, and fiber laser hair removal systems. Shenzhen Lifotronic Technology Co., Ltd. was founded in 2008 and is headquartered in Shenzhen, China.